Read by QxMD icon Read

Clinical Breast Cancer

Meiying Yan, Jingxuan Wang, Qijia Xuan, Tieying Dong, Juan He, Qingyuan Zhang
PURPOSE: To investigate the relationship between tamoxifen-associated nonalcoholic fatty liver disease (NAFLD) and survival outcomes in patients with breast cancer. METHODS: Patients with early-stage invasive breast cancer after curative resection from January 2009 to June 2011 were selected. A total of 646 patients who were treated with tamoxifen were included. Patients diagnosed with NAFLD on ultrasonography were classified into the NAFLD and non-NAFLD groups...
December 24, 2016: Clinical Breast Cancer
Shadia M Al-Bahlani, Khadija H Al-Bulushi, Zaina M Al-Alawi, Nadia Y Al-Abri, Zuweina R Al-Hadidi, Shaikha S Al-Rawahi
BACKGROUND: Breast cancer is the most common cancer in women worldwide. Triple-negative breast cancer (TNBC) is an aggressive type that can be treated using platinum-based chemotherapy such as cisplatin (cis-diamminedichloroplatinum II). Although the calpain protein is essential in many cellular processes, including apoptosis, cell signaling, and proliferation, its role in cisplatin-induced apoptosis in TNBC cells is not fully understood. The present study assessed calpain 1-dependent, cisplatin-induced apoptosis in TNBC cells...
December 24, 2016: Clinical Breast Cancer
Cynthia Brito Lins Pereira, Mariana Ferreira Leal, Eliana Saul Furquim Werneck Abdelhay, Sâmia Demachki, Paulo Pimentel Assumpção, Mirian Carvalho de Souza, Caroline Aquino Moreira-Nunes, Adriana Michiko da Silva Tanaka, Marília Cardoso Smith, Rommel Rodríguez Burbano
BACKGROUND: Neoadjuvant chemotherapy is a standard treatment for stage II and III breast cancer. The identification of biomarkers that may help in the prediction of response to neoadjuvant therapies is necessary for a more precise definition of the best drug or drug combination to induce a better response. MATERIAL AND METHODS: We assessed the role of Ki67, hormone receptors expression, HER2, MYC genes and their protein status, and KRAS codon 12 mutations as predictor factors of pathologic response to anthracycline-cyclophosphamide (AC) followed by taxane docetaxel (T) neoadjuvant chemotherapy (AC+T regimen) in 51 patients with invasive ductal breast cancer...
December 24, 2016: Clinical Breast Cancer
Catherine Benedict, Bridgette Thom, Eleonora Teplinsky, Jane Carleton, Joanne F Kelvin
Adherence to endocrine therapy (ET) is a longstanding problem in breast cancer (BC) survivorship care, particularly among younger women. Younger patients have reported lower ET initiation rates and greater rates of early discontinuation and are considered an "at risk" group for nonadherence. For women who hope to have children in the future, concerns about premature menopause and the implications of postponing childbearing for the 5 to 10 years of ET are widespread. Preliminary evidence suggests that prioritizing fertility, along with concerns about side effects, leads to ET noninitiation and early discontinuation...
December 24, 2016: Clinical Breast Cancer
Roberto Agresti, Marco Sandri, Massimiliano Gennaro, Giulia Bianchi, Ilaria Maugeri, Mario Rampa, Giuseppe Capri, Maria Luisa Carcangiu, Giovanna Trecate, Egidio Riggio, Laura Lozza, Filippo de Braud
BACKGROUND: Nipple-areola complex-sparing mastectomy (NSM), extending the concept of skin-sparing mastectomy, allows for the provision of a better cosmetic result. Large operable T2-T3 breast cancer might theoretically appear suitable for this surgical option as an alternative to conventional mastectomy or breast-conserving surgery, when a good response to primary chemotherapy has been achieved. PATIENTS AND METHODS: From January 2009 to May 2013, 422 patients with invasive breast cancer were progressively accrued to NSM...
December 24, 2016: Clinical Breast Cancer
Cynthia Villarreal-Garza, Alejandro Mohar, Juan Enrique Bargallo-Rocha, Federico Lasa-Gonsebatt, Nancy Reynoso-Noverón, Juan Matus-Santos, Paula Cabrera, Claudia Arce-Salinas, Fernando Lara-Medina, Alberto Alvarado-Miranda, María Teresa Ramírez-Ugalde, Enrique Soto-Perez-de-Celis
INTRODUCTION: Young age represents an adverse prognostic factor in breast cancer (BC), and young women present with more advanced and aggressive disease. In Latin America, BC is increasing in young women, and there is a lack of information regarding the characteristics and outcomes of this patient population. PATIENTS AND METHODS: We retrospectively analyzed a database of 4315 women treated for BC at a single institution. We compared clinical characteristics, treatment, and survival between women ≤ 40 and > 40 years of age...
November 23, 2016: Clinical Breast Cancer
Feng Xiao, Xue Song, Qianjun Chen, Yan Dai, Rui Xu, Chang Qiu, Qianqian Guo
The present study assessed the effectiveness of individually delivered cognitive behavioral therapy (CBT) interventions in improving depression in patients with breast cancer. A systematic search of Medline (Ovid), PubMed, Cochrane Library, China National Knowledge Infrastructure database, WANFANG, and the VIP database. Quality assessment of included studies was conducted by 2 reviewers independently using the Jadad scale. The pooled effect of the mean difference in the baseline and post-treatment depressive scores was analyzed using different outcome measuring instruments (Self-rating Depression Scale, Hospital Anxiety and Depression Scale, and Hamilton Depression Rating Scale) separately...
November 23, 2016: Clinical Breast Cancer
Alexandra Giatromanolaki, Efthimios Sivridis, Dimitra Kalamida, Michael I Koukourakis
BACKGROUND: Disrupting the autophagic balance to trigger autophagic death may open new strategies for cancer therapy. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and may play a role in cancer biology and clinical behavior. METHODS: The expression of TFEB and the lysosomal cancer cell content (expression of lysosomal associated membrane protein 2a [LAMP2a] and cathepsin D) was studied in a series of 100 T1-stage breast carcinomas...
November 23, 2016: Clinical Breast Cancer
Chin-Hsiao Tseng
BACKGROUND: Whether sitagliptin may affect breast cancer risk remains to be answered. This study evaluated such an association in Taiwanese female patients with type 2 diabetes. METHODS: A retrospective cohort of female patients with newly diagnosed type 2 diabetes at an age ≥ 25 years between 1999 and 2010 was recruited from the National Health Insurance database. A total of 32,457 ever-users and 396,021 never-users of sitagliptin were followed until December 31, 2011...
November 23, 2016: Clinical Breast Cancer
Keiko Sato, Kazunori Akimoto
INTRODUCTION: In general, it has been considered that estrogen receptor-positive (ER(+)) breast cancer has a good prognosis and is responsive to endocrine therapy. However, one third of patients with ER(+) breast cancer exhibit endocrine therapy resistance, and many patients develop recurrence and die 5 to 10 years after diagnosis. In ER(+) breast cancer, a major problem is to distinguish those patients most likely to develop recurrence or metastatic disease within 10 years after diagnosis from those with a sufficiently good prognosis...
November 23, 2016: Clinical Breast Cancer
Anne E Mattingly, Blaise Mooney, Hui-Yi Lin, John V Kiluk, Nazanin Khakpour, Susan J Hoover, Christine Laronga, M Catherine Lee
BACKGROUND: Breast magnetic resonance imaging (MRI) for assessment of regional breast cancer metastasis is controversial owing to the variable specificity. We evaluated breast MRI for axillary metastasis in neoadjuvant chemotherapy patients. MATERIALS AND METHODS: A single-institution, institutional review board-approved prospective trial enrolled female breast cancer patients receiving neoadjuvant chemotherapy from 2008 to 2012 and collected the pre- and post-treatment MRI, pretreatment axillary ultrasound, axillary biopsy, and surgical pathologic findings...
November 23, 2016: Clinical Breast Cancer
Mahvish Muzaffar, Swapnil Kachare, Nasreen Vohra
BACKGROUND: Primary tumor surgery (PTS) is not a standard treatment modality in stage IV breast cancer. Retrospective studies in female breast cancer show improved survival in women undergoing PTS; however, data regarding the impact of surgery in male breast cancer are lacking. The objective of this study was to analyze the impact of PTS on survival among men with metastatic breast cancer. METHODS: A retrospective study was conducted of men diagnosed with metastatic breast cancer at diagnosis were identified from the Surveillance, Epidemiology, and End Results (SEER) database from 1988 to 2011...
November 22, 2016: Clinical Breast Cancer
Jai Min Ryu, Sungmin Park, Hyun-June Paik, Seok Jin Nam, Seok Won Kim, Se Kyung Lee, Jonghan Yu, Soo Youn Bae, Isaac Kim, Sa Ik Bang, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon, Jeong Eon Lee
INTRODUCTION: Although the indication for immediate breast reconstruction (IBR) after skin-sparing mastectomy (SSM) or nipple-sparing mastectomy (NSM) has been expanded, IBR after neoadjuvant chemotherapy (NACT) is still controversial. We conducted retrospective matched case-control study to analyze oncologic outcomes between patients who underwent TM only and those who underwent IBR after SSM or NSM after NACT. PATIENTS AND METHODS: A retrospective review of breast cancer patients who underwent IBR after SSM or NSM after NACT between 2008 and 2015 at a single center was conducted...
October 27, 2016: Clinical Breast Cancer
Savaş Serel, Zeynep Yasavur Tuzlalı, Zehra Akkaya, Çağlar Uzun, Burak Kaya, Sancar Bayar
OBJECTIVE: Mastectomy is known to effect body posture after a change in the center of gravity of women due to a missing breast. Although previous studies on short-term postural changes in mastectomy patients using photogrammetry or Moiré topography suggested ipsilateral inclination of the trunk, our clinical observations during breast reconstruction surgeries indicated a contralateral shoulder elevation in women with unilateral mastectomy. Because the change in body posture can affect spinal alignment, we aimed to evaluate the long-term physical effects of unilateral mastectomy on spine deformity by radiographic examination...
October 26, 2016: Clinical Breast Cancer
Karen A Cadoo, Patrick G Morris, Elizabeth P Cowell, Sujata Patil, Clifford A Hudis, Heather L McArthur
INTRODUCTION: The benefit of adjuvant trastuzumab with chemotherapy is well established for women with higher risk human epidermal growth factor receptor 2-positive (HER2(+)) breast cancer. However, its role in older patients with smaller, node-negative tumors is less clear. We conducted a retrospective, sequential cohort study of this population to describe the impact of trastuzumab on breast cancer outcomes and cardiac safety. PATIENTS AND METHODS: Women ≥ 55 years with ≤ 2 cm, node-negative, HER2(+) breast cancer were identified and electronic medical records reviewed...
December 2016: Clinical Breast Cancer
Denise A Yardley, James Reeves, E Claire Dees, Cynthia Osborne, Devchand Paul, Foluso Ademuyiwa, Hatem Soliman, Troy Guthrie, Jay Andersen, Lea Krekow, Janak Choksi, Brooke Daniel, Michael Danso, Anne Favret, Sanjay Oommen, Adam Brufsky, Jane L Bromund, Yong Lin, Ayman B Ibrahim, Paul D Richards
BACKGROUND: Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as third- to fifth-line therapy in women with advanced breast cancer. PATIENTS AND METHODS: In this randomized (1:1), open-label, phase II study, US women aged 18 years or older with 2 to 4 previous chemotherapy regimens for locally recurrent or MBC, previous anthracycline and taxane treatment, and Eastern Cooperative Oncology Group performance status of 0 or 1 received ramucirumab with eribulin or eribulin alone in 21-day cycles (eribulin 1...
December 2016: Clinical Breast Cancer
Woo Jung Choi, Joo Hee Cha, Hak Hee Kim, Hee Jung Shin, Eun Young Chae
BACKGROUND: The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS: Eight hundred women were included. The maximum diameter of the tumor was measured on T2-weighted (T2W) sequences, early-subtracted dynamic contrast-enhanced (DCE) T1-weighted (T1W) sequences, and maximal intensity projection (MIP) reconstructions...
December 2016: Clinical Breast Cancer
Shaan Dudani, Sasha Mazzarello, John Hilton, Brian Hutton, Lisa Vandermeer, Ricardo Fernandes, Mohammed F K Ibrahim, Stephanie Smith, Habeeb Majeed, Khalid Al-Baimani, Jean-Michel Caudrelier, Risa Shorr, Mark Clemons
The incidence of leptomeningeal carcinomatosis in breast cancer patients (LC-BC) is increasing. Despite significantly affecting patient quality of life (QoL) and overall survival (OS), little is known about its optimal management. A systematic review of treatment strategies for LC-BC was performed. EMBASE, Ovid Medline, Pubmed, and the Cochrane Central Register of Controlled Trials were searched from 1946 to 2015 for trials reporting on treatments for LC-BC. All treatment modalities and study types were considered...
December 2016: Clinical Breast Cancer
Qijia Xuan, Kun Gao, Ying Song, Shu Zhao, Lina Dong, Zhongbai Zhang, Qingyuan Zhang, Jingxuan Wang
PURPOSE: The purpose of this study was to evaluate the differences in stage upon diagnosis, adherence to adjuvant treatment, and recurrence between rural and urban patients with early breast cancer. METHODS: This retrospective study included 3640 patients with primary breast cancer recruited from 2000 to 2009. Patients who developed recurrence or metastasis were verified by adequate diagnostic imaging modalities and pathology. The χ(2) test was used to compare groups with respect to variables (recurrence and clinicopathologic features)...
December 2016: Clinical Breast Cancer
Kimihiro Tanaka, Eriko Tokunaga, Yuka Inoue, Nami Yamashita, Hiroshi Saeki, Shinji Okano, Hiroyuki Kitao, Eiji Oki, Yoshinao Oda, Yoshihiko Maehara
BACKGROUND: The association between Axl and vimentin protein expression has been observed in several cell lines. However, the clinical importance of Axl and vimentin expression in breast cancer have not been fully determined. PATIENTS AND METHODS: The expressions of Axl and vimentin were evaluated by immunohistochemistry in a total of 343 patients with invasive ductal carcinoma. The relationships between expression of Axl and vimentin and clinicopathologic characteristics and prognosis were analyzed...
December 2016: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"